Lung Cancer: Targets and Therapy, Volume 14, Issue (2023)

Browse this journal
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Lung Cancer: Targets and Therapy, Volume 14, Issue (2023)

See all volumes and issues
Vol 15, 2024 Volume 14, 2023 Vol 13, 2022 Vol 12, 2021 Vol 11, 2020 Vol 10, 2019 Vol 9, 2018 Vol 8, 2017 Vol 7, 2016 Vol 6, 2015 Vol 5, 2014 Vol 4, 2013 Vol 3, 2012 Vol 2, 2011 Vol 1, 2010
Download citations Download PDFs Download issue

REVIEW

Review
Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno
Danielle Brazel, Sai-Hong Ignatius Ou & Misako Nagasaka
Pages: 1-9
Published online: 05 Jan 2023
AbstractforTiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno | Full Text | References | PDF (409.3 KB) | EPUB
  • 556 Views
  • 6 CrossRef citations
  • 0Altmetric
Open Access
Review
Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review
Maria Concetta Nigro, Paola Valeria Marchese, Chiara Deiana, Chiara Casadio, Linda Galvani, Alessandro Di Federico & Andrea De Giglio
Pages: 11-25
Published online: 03 Feb 2023
AbstractforClinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review | Full Text | References | PDF (3 MB) | EPUB
  • 497 Views
  • 4 CrossRef citations
  • 0Altmetric
Open Access

COMMENTARY

Article Commentary
CodeBreak 200: Sotorasib Has Not Broken the KRASG12C Enigma Code
Shannon S Zhang, Alexandria Lee & Misako Nagasaka
Pages: 27-30
Published online: 19 Apr 2023
AbstractforCodeBreak 200: Sotorasib Has Not Broken the KRASG12C Enigma Code | Full Text | References | PDF (316.3 KB) | EPUB
  • 390 Views
  • 0 CrossRef citations
  • 0Altmetric
Open Access
Article Commentary
CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code
Danielle Brazel, Jennifer Kim & Sai-Hong Ignatius Ou
Pages: 31-39
Published online: 20 Apr 2023
AbstractforCodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code | Full Text | References | PDF (418.5 KB) | EPUB
  • 531 Views
  • 0 CrossRef citations
  • 0Altmetric
Open Access
Article Commentary
CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC
Alexandria TM Lee & Misako Nagasaka
Pages: 41-46
Published online: 25 Apr 2023
AbstractforCheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC | Full Text | References | PDF (337.9 KB) | EPUB
  • 399 Views
  • 1 CrossRef citations
  • 0Altmetric
Open Access

ORIGINAL RESEARCH

Article
Effect of Lymphopenia on Tumor Response and Clinical Outcomes Following Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer
Jared Deck, Marissa Hartley, Mohammad Akhter, Dongliang Wang, Jeffrey A Bogart & Michael D Mix
Pages: 47-55
Published online: 19 May 2023
AbstractforEffect of Lymphopenia on Tumor Response and Clinical Outcomes Following Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer | Full Text | References | PDF (2.1 MB) | EPUB
  • 239 Views
  • 0 CrossRef citations
  • 0Altmetric
Open Access

COMMENTARY

Article Commentary
From ASCEND-5 to ALUR to ALTA-3, an Anti-Climactic End to the Era of Randomized Phase 3 Trials of Next-Generation ALK TKIs in the Crizotinib-Refractory Setting
Alexandria TM Lee & Saihong Ignatius Ou
Pages: 57-62
Published online: 22 Jun 2023
AbstractforFrom ASCEND-5 to ALUR to ALTA-3, an Anti-Climactic End to the Era of Randomized Phase 3 Trials of Next-Generation ALK TKIs in the Crizotinib-Refractory Setting | Full Text | References | PDF (360.9 KB) | EPUB
  • 183 Views
  • 0 CrossRef citations
  • 0Altmetric
Open Access
Article Commentary
The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC?
Danielle Brazel & Saihong Ignatius Ou
Pages: 63-69
Published online: 23 Jun 2023
AbstractforThe Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC? | Full Text | References | PDF (371.6 KB) | EPUB
  • 206 Views
  • 0 CrossRef citations
  • 0Altmetric
Open Access

PERSPECTIVES

Article Commentary
ALESIA 5-Year Update: Alectinib at 600 mg Twice Daily Gives Lorlatinib a Run for Its Money in Asia
Alexandria TM Lee & Saihong Ignatius Ou
Pages: 71-78
Published online: 07 Jul 2023
AbstractforALESIA 5-Year Update: Alectinib at 600 mg Twice Daily Gives Lorlatinib a Run for Its Money in Asia | Full Text | References | PDF (354.8 KB) | EPUB
  • 306 Views
  • 0 CrossRef citations
  • 0Altmetric
Open Access

CASE REPORT

Case Report
Co-Occurring EGFR S645C and EGFR L858R in a Patient with Lung Adenocarcinoma Induced Primary Resistance to Osimertinib
Li Wang, Fei Quan, Zhen Guo, Zhongyu Lu, Duoxia Yang & Meiqi Shi
Pages: 79-84
Published online: 09 Oct 2023
AbstractforCo-Occurring EGFR S645C and EGFR L858R in a Patient with Lung Adenocarcinoma Induced Primary Resistance to Osimertinib | Full Text | References | PDF (3.1 MB) | EPUB
  • 142 Views
  • 1 CrossRef citations
  • 0Altmetric
Open Access

ORIGINAL RESEARCH

Article
Single-Cell Profiling of Tumor-Associated Neutrophils in Advanced Non-Small Cell Lung Cancer
Jinpeng Shi, Jiayu Li, Haowei Wang, Xuefei Li, Qi Wang, Chao Zhao, Lei Cheng, Ruoshuang Han, Peixin Chen, Haoyue Guo, Zhuoran Tang, Caicun Zhou, Zhemin Zhang & Fengying Wu
Pages: 85-99
Published online: 20 Nov 2023
AbstractforSingle-Cell Profiling of Tumor-Associated Neutrophils in Advanced Non-Small Cell Lung Cancer | Full Text | References | PDF (11.8 MB) | EPUB
  • 233 Views
  • 0 CrossRef citations
  • 0Altmetric
Open Access

COMMENTARY

Article Commentary
Stage as the Sole “Biomarker” for Adjuvant Pembrolizumab in Resected Stage IB to IIIA NSCLC without Considerations for PD-L1 Expression Level, ALK/EGFR Mutational Status, and Prior Adjuvant Chemotherapy per FDA Approval Indications of PEARLS/Keynote-091?
Misako Nagasaka & Saihong Ignatius Ou
Pages: 101-109
Published online: 12 Dec 2023
AbstractforStage as the Sole “Biomarker” for Adjuvant Pembrolizumab in Resected Stage IB to IIIA NSCLC without Considerations for PD-L1 Expression Level, ALK/EGFR Mutational Status, and Prior Adjuvant Chemotherapy per FDA Approval Indications of PEARLS/Keynote-091? | Full Text | References | PDF (401.4 KB) | EPUB
  • 175 Views
  • 0 CrossRef citations
  • 0Altmetric
Open Access

Explore articles

Explore the most recently published articles

HMGB1 Expression Levels Correlate with Response to Immunotherapy in Non-Small Cell Lung Cancer
Maria González-Cao et al.
Article | Published online: 9 May 2024
Open Access
The Butterfly Flies - Practice Changing Results of PAPILLON, First Line Chemotherapy and Amivantamab for the Treatment of NSCLC Patients with EGFR Exon 20 Insertions
Dalia Kaakour et al.
Article Commentary | Published online: 23 Apr 2024
Open Access
MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting?
Danielle Brazel et al.
Article Commentary | Published online: 12 Apr 2024
Open Access
Effectiveness and Safety of Anlotinib Combined with PD-1 Blockades in Patients with Previously Immunotherapy Treated Advanced Non-Small Cell Lung Cancer: A Retrospective Exploratory Study
Xue-Jun Dou et al.
Article | Published online: 25 Mar 2024
Open Access